Substitute for form 1449/PTO			Complete if Known		
			Application Number	10/608,723-Conf. #6915	
IFORMATIO	N DI	SCLOSURE	Filing Date	June 26, 2003	
STATEMENT BY APPLICANT			First Named Inventor	Andrew R. MARKS	
			Art Unit	1646	
(Use as many sheets as necessary)			Examiner Name	R. Li	
1	of	1	Attorney Docket Number	0019240.00594US1	
	IFORMATIC TATEMENT	IFORMATION DI TATEMENT BY A	IFORMATION DISCLOSURE TATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number Filing Date Filing Date First Named Inventor (Use as many sheets as necessary) Application Number Filing Date First Named Inventor Art Unit Examiner Name	

U.S. PATENT DOCUMENTS					
Examiner Inflais*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,963,671	10-16-1990	Krapcho	
	AB*	US-3,519,647	07-07-1970	Krapcho	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶	
						Г	

"EXAMINE: Inside If reference considered, whether or not distalen is no conformance with NEPP (90). Does the through citation if not in conformance and not considered, broadles copy of this from with note communication logistics." ICET NOT home applicationly which are maked with a mining electrick (*) made to the Cline No. are not supplied (noter 37 CPR § 196(s)(2)(iii)) because that application was field after June 30, 0000 or is evaluate in the IPN. * Applicant's unique calculate designation number (optional)** "See Riscal Codes" in USET/OF death Documents at www.cost(2)(iii) or APP 07 07 01.6. * Extent Office and its activated in the IPN. * Applicant's unique calculated estimates on APP 07 01.6. * Extent Office and its activate of the IPN 0.6. * Applicant's unique calculated estimates a wide of the IPN 0.6. * Applicant's unique calculated estimates a wide of the IPN 0.6. * Applicant's unique calculated estimates of the patient document. * Find of document by the appropriate symbols as indicated on the document under VMPO Standard ST.18 of possible. * Applicant to place a clinic calculated or the document under VMPO Standard ST.18 of possible. * Applicant to place a clinic calculated or the document under VMPO Standard ST.18 of possible. * Applicant to place a clinic calculated or the document under VMPO Standard ST.18 of possible. * Applicant of the IPN 0.6. * Applicant of ST.18 of possible. * Applicant of the IPN 0.6. * Applicant of ST.18 of possible. * Applicant of the IPN 0.6. * Applicant of ST.18 of IPN 0.6. * Applican

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T?		
	CA**	Gailly, "New Aspects of Calcium signaling in skeletal muscle cells: implications in Duchenne muscular Dystrophy," Biochimica et Biophysica Acta, Vol 1600, pp. 38-44 (2002)			
	CB**	International Preliminary Report on Patentability from International Application PCT/US2005/010055, mailed October 4, 2007	Г		
	CC**	International Preliminary Report on Patentability from International Application PCT/US2005/010056, mailed October 4, 2007			
	CD**	International Search Report and Written Opinion from International Patent Application No PCT/US06/32405, December 7, 2007	Г		
	CE**	LaFerla, "Calcium Dyshomeostasis and Intracellular signalling in Alzheimer's disease," Nature Reviews, Vol 3, pp. 862-872 (November 2002)			
	CF**	Mackenzie et all, "The Role of inositol 1,4,5-trisphosphate receptors in Ca2+ signalling and the generation of arrhythmias in rat atrila myocytes," J. Physiol., Vol 541, pp. 395-409 (2002)			
	CG**	Taur et al., "The Cardiac Ryanodine Receptor (RyR2) and its Role in Heart Disease," Cardiology in Review, Volume 13, No 3, pp. 142-146 (2005)			

EXAMINER Initial fireference considered, whether or not clusion is in conformance with MPEP 609. Draw kine through clusion if not in conformance and not considered, include coly of this file film with not communication to application. "CTE NO. Those documently) which are marted with an double selection (") considered in the conformance and not considered with an advantage of the conformance and not considered with an advantage of the conformance and not considered with a conformance and not conformance and not considered with a conformance and not considered

1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.L./

Examiner	/Buixiang Li/	Date	00/40/0000
Signature	Trainiang Li	Considered	03/12/2008
6500404			